Chromocell Therapeutics Corp

09/18/2024

It's . Did you know one-third of the U.S. population suffers from chronic pain? Chromocell is dedicated to developing innovative, non-addictive treatments to address this unmet need. See our pipeline here: https://bit.ly/3w5WNbt

09/11/2024

- Chromocell CEO Frank Knuettel discussed Chromocell's progress and strategy in pioneering innovative non-opioid pain treatment therapeutics during the H.C. Wainwright 26th Annual Global Investment Conference. Watch a replay of his presentation here:

We use cookies to offer you a better browsing experience, including personalized advertising. By continuing to use the site you agree to their use.

09/10/2024

September is Pain Awareness Month. At Chromocell, we are committed to making a difference by developing non-opioid alternatives for pain treatment. Learn more about our innovative clinical programs that are paving the way for safer, more effective solutions:

Our Pipeline

09/06/2024

Dr. Stephen Waxman, chair of our Scientific Advisory Board, is one of the foremost experts in NaV research. Learn more about our accomplished team of scientific advisors guiding our clinical development:

Management Team Frank Knuettel II Chief executive officer and chief financial officer Knuettel has 30 years of management experience, growing early-stage and smallcap public companies. He has spent most of his career as a Chief Financial or Chief Strategic Officer at early-stage companies. He has ra...

09/04/2024

Our management team, board of directors, and scientific advisors are composed of accomplished business leaders, industry-leading experts in pain research and management, and experienced clinical development professionals. Read more about Chromocell's leadership: https://bit.ly/48C8xPT

09/03/2024

Chromocell will be featured as a presenting company at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11. Frank Knuettel, CEO of Chromocell, will provide a corporate overview during the presentation. For more information, including how to schedule a one-on-one meeting, visit: https://bit.ly/3z53U5d

08/28/2024

Don't miss an update. Get the latest Chromocell company press releases, filings and special announcements by signing up for email alerts: https://bit.ly/3wX6qcW

08/26/2024

Small fiber neuropathy may begin with mild discomfort, but the pain can often become debilitating and affect quality of life. New treatments are needed to help those suffering from small fiber neuropathy. Learn more about the condition here:

Tingling or numbness in the feet or hands followed by painful or burning sensations could be a sign of small-fiber neuropathy. This condition should be checked out, as it could be a symptom of some...

08/15/2024

Chromocell has launched a share repurchase plan as we continue to develop groundbreaking treatments for neuropathic and chronic pain. Find out more. https://bit.ly/4clr5Wu

08/13/2024

Focused on enhancing shareholder value, Chromocell has introduced a $250,000 stock repurchase plan while continuing to drive innovation in non-opioid pain treatments. Stay tuned for upcoming updates on our drug development efforts. https://bit.ly/4clr5Wu

08/12/2024

Chromocell Chief Executive Officer and President, Frank Knuettel, comments on the recent announcement of the Company's stock repurchase plan. Learn more here: https://bit.ly/4clr5Wu

08/12/2024

Chromocell’s Board of Directors have authorized a strategic stock repurchase plan, citing the current stock price as an attractive investment, which the Company believes may enhance shareholder value. The company remains committed to advancing our pipeline of neuropathic and chronic pain treatments. https://bit.ly/4clr5Wu